NCT01283373 (Clinical Trial / Vandortuzumab Vedotin / DSTP3086S)

Study Title
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT01283373)

Trial Description
This is a Phase I, multicenter, open-label, dose-escalation study of DSTP3086S, also known as vandortuzumab vedotin, administered as a single agent by intravenous (IV) infusion to patients with metastatic Castration-Resistant Prostate Cancer (mCRPC).

This trial is sponsored by Genentech. [1]

Study Data

  • Condition: Prostate Cancer
  • Interventions:
  • Phase: I
  • Estimated Enrollment: 87
  • Start: March 2011
  • Estimated Completion: June 2016
  • Last verified: May 2015

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: July 14, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.